20th-22nd March

London, UK

Download Brochure

Speakers

Expand/Collapse

David Solomon
Chief Executive Officer
Akari Therapeutics

David Horn Solomon is the Chief Executive Officer of Akari Therapeutics (NASDAQ: AKTX): He joined the Company in August 2017. Prior to joining the Company, Dr. Solomon was Managing Partner of SundCapital ApS, a healthcare investment fund based in Copenhagen, Denmark, a position he held since 2016. From 2015 to 2016, Dr. Solomon was Chief Executive Officer of Bionor A/S (OSLO: BIONOR) and from 2008 to 2015 he was the Chief Executive Officer of Zealand Pharma A/S (Nasdaq: ZEAL). Since 2015, Dr. Solomon has served as a Board Member and Chair of the Remuneration and Compensation Committee of TxCell S.A. (NYSE Euronext: TXCL) and Dr. Solomon previously served on the boards of Onxeo SA (NYSE Euronext and NASDAQ: ONXEO) from 2011 to 2017 and Promosome, LLC from 2014 to 2017. Dr. Solomon previously held senior positions at Carrot Capital and Vital Sensors, and served as a faculty member at Columbia University’s College of Physicians and Surgeons. Dr. Solomon studied at Cornell University’s Weil Medicine and its Graduate School of Medical Science/ Sloan Kettering Division in New York where he received his Ph.D. in 1991.

Day Two

Thursday March 22nd, 2018

11.45 | Coversin: The Role in the Treatment of Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome

Simon Read
CSO
Ra Pharma

Sandip Panicker
Executive Director
Bioverativ Inc.

Sandip Panicker, Ph.D., is Executive Director of Complement Research at Bioverativ Inc., where he oversees the discovery and pre-clinical efforts on complement programs. Dr. Panicker is the scientific champion behind BIVV009, a first-in-class humanized monoclonal antibody that inhibits the classical pathway specific serine protease, C1s. Sandip has also been involved with the clinical study designs and regulatory submissions and interactions that have led to the orphan and breakthrough designation status of BIVV009 for the treatment of cold agglutinin disease.

Day Two

Thursday March 22nd, 2018

12.15 | Development of BIVV009 for the Treatment of Patients with Primary Cold Agglutinin Disease (CAgD)

Anna Blom
Professor of Medical Protein Chemistry
Lund University

Dr Anna Blom is a professor of medical protein chemistry at Lund University, Sweden and she is also associated with Clinical Chemistry (Region Skåne). For the last 20 years she has been investigating complement inhibitors and imbalance between complement activation and inhibition in rheumatic diseases, cancer and infections. She has also studied structure-function relationships for complement inhibitors such as factor I, C4BP, CD46 and factor H including effects of mutations in these inhibitors found in diseases such as hemolytic uremic syndrome and age-related macula degeneration.

Day Two

Thursday March 22nd, 2018

09.45 | Therapeutically Harnessing the Role of Complement in Infection - Complement Evasion Strategies Developed by Bacterial Pathogens

Michael Holers
Scoville Professor & Head, Division of Rheumatology
University of Colorado

Day Two

Thursday March 22nd, 2018

14.45 | Panel: Balancing Benefits and Risks by Assessing Optimum Inhibition Levels for Key Diseases

09.15 | Advances in Understanding of Disease Pathogenesis in Rheumatoid Arthritis and Systemic Lupus Erythematosus Open Up New Opportunities for Complement Therapeutics

Paul Morgan
Professor of Immunology and Director, Systems Immunity Research Institute
Cardiff University

Afternoon Workshop

Tuesday March 20th, 2018

13.00 |

Recognising the Potential of Complement in Neurodegeneration: From the Fundamental Science to Clinical Development

Day Two

Thursday March 22nd, 2018

16.45 | Chairman’s Closing Remarks

14.45 | Panel: Balancing Benefits and Risks by Assessing Optimum Inhibition Levels for Key Diseases

Eva-Maria Nichols
Head of Complement
GlaxoSmithKline

Morning Workshop

Tuesday March 20th, 2018

09.00 |

Optimising Complement-based Clinical Trial Design for Expansion Beyond Ultra-Rare Diseases

Day Two

Thursday March 22nd, 2018

15.45 | Approaches to Computational Modelling of the Complement System

Michael Kirschfink
Professor of Immunology
University of Heidelberg

Day Two

Thursday March 22nd, 2018

14.45 | Panel: Balancing Benefits and Risks by Assessing Optimum Inhibition Levels for Key Diseases

Frank Baas
CSO
Complement Pharma

Afternoon Workshop

Tuesday March 20th, 2018

13.00 |

Recognising the Potential of Complement in Neurodegeneration: From the Fundamental Science to Clinical Development

Ashley Frazer-Abel
Director
Exsera Biolabs

Andrea Tenner
Professor of Molecular Biology & Biochemistry
University of California

Anne Bruns
Executive Director
aHUS Foundation

Day Two

Thursday March 22nd, 2018

12.45 | The Power of Complement Therapeutics: A Patient Perspective

Kiran Nistala
Experimental Medicine Physician
GlaxoSmithKline

Morning Workshop

Tuesday March 20th, 2018

09.00 |

Optimising Complement-based Clinical Trial Design for Expansion Beyond Ultra-Rare Diseases

Kai Höhlig
Senior Scientist & Project Manager
Aptarion Biotech AG

Richard Smith
Director, Protein Therapeutics Laboratory
King’s College London

Day Two

Thursday March 22nd, 2018

14.15 | Cytotopic Complement Inhibitors – Mechanisms and Insights

Tom Mollnes
Professor of Immunology and Leader, Complement Research Group
University of Oslo

Day Two

Thursday March 22nd, 2018

10.15 | Dual blockade of complement C3/C5 and TLR/CD14 as a Novel Treatment Approach for Sepsis and SIRS.

Erik Hack
CSO
Prothix

Anna Schubart
Investigator III
Novartis

Day Two

Thursday March 22nd, 2018

16.15 | Details of this presentation aren’t available at this stage, please check back for further details.

Andrea Tenner
Professor of Molecular Biology & Biochemistry
University of California